May 15, 2025 04:52 AM EDTUpdated 06:30 AM

Hengrui, one of China's leading biotechs, anticipates $1.2B in proposed Hong Kong listing

Kyle LaHucik

Senior Reporter

Jiangsu Hengrui, a 55-year-old drugmaker that has become one of China’s leading forces in biotech, expects net proceeds of about 9.4 billion Hong Kong dollars …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

Hengrui, one of China's leading biotechs, anticipates $1.2B in proposed Hong Kong listing

Kyle LaHucik

Senior Reporter

Sign up to read this article for free.

VP, Clinical Development / CMO / CDO‬ ‭ (Stealth Portfolio Company)

Autonomy Bio Inc.

San Francisco, CA 94107, USA

Biohaven stock sinks on three-month delay for neuro drug's FDA approval decision

Exclusive: Drug compounder Empower was built on risky shortcuts, ex-employees and inspections allege

Updated: Merck KGaA continues US tariff surcharge but at a 'decreased' rate

Bristol Myers CEO says America’s biopharma pole position is not guaranteed

FDA gives AbbVie accelerated approval for antibody-drug conjugate in lung cancer

Pathos AI collects $365M to fuel 'bulletproof' oncology trials and in-license more cancer drugs

Hen­grui, one of Chi­na's lead­ing biotechs, an­tic­i­pates $1.2B in pro­posed Hong Kong list­ing

Senior Reporter

Sign up to read this article for free.

more like this

Autonomy Bio Inc.

San Francisco, CA 94107, USA

Hengrui, one of China's leading biotechs, anticipates $1.2B in proposed Hong Kong listing